This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Oral Budesonide Suspension
Shire Pharmaceuticals Group PLC
Drug Names(s): oral viscous budesonide, MB-7, SHP621, SHP636, OBS
Oral Budesonide Suspension is a proprietary formulation that is viscous and is designed to coat the esophagus with budesonide where it acts topically. OBS is designed to coat the esophagus with budesonide in order to treat local eosinophilic inflammation and provide patients symptomatic relief. Budenoside is a glucocorticoid that is very rapidly metabolized by the liver when absorbed systemically, thus limiting systemic exposure and the potential for glucocorticoid side effects.
Shire labels its Oral Budesonide Suspension under 2 seperate Shire tags: SHP621, SHP636.
ViroPharma and Meritage
In December 2011, ViroPharma announced that it has entered into an exclusive option to acquire Meritage. ViroPharma paid an initial $7.5 million, and agreed to provide Meritage up to an additional $12.5 million for the development and exclusive right to purchase the company at predefined terms upon the completion of a series of clinical and regulatory deliverables. Meritage will utilize the funding to conduct additional Phase II clinical assessment of OBS. After receipt of final Phase II data and concurrence with the U.S. Food and Drug Administration (FDA) on an acceptable clinical endpoint for the Phase III program, ViroPharma will have an option to acquire Meritage at ViroPharma's discretion for $69.9 million plus the potential for additional payments upon the achievement of certain clinical and regulatory milestones.
ViroPharma and Shire
In November 2013, Shire and ViroPharma entered into a merger agreement pursuant to which...See full deal structure in Biomedtracker
Oral Budesonide Suspension News
Pink Sheet European CHMP Opinions and MAA Updates
Additional information available to subscribers only: